ArticleAmerican journal of ophthalmology case reports2020
Advanced Coats' disease treated with intravitreal brolucizumab combined with laser photocoagulation.
Article in American journal of ophthalmology case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Therapeutic effect of faricimab in macular telangiectasia type 1 and Coats' disease: case series.BMC ophthalmology · 2026Article
- Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Multimodal treatment of Coats-like exudative vitreoretinopathy in Goldmann-Favre syndrome.American journal of ophthalmology case reports · 2022Article
- Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.Drug design, development and therapy · 2022Review
- Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world.Eye (London, England) · 2021Article
- Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab.American journal of ophthalmology case reports · 2020Article
- A Brief Review on Adult-Onset Coats' Disease.Romanian journal of ophthalmologyReview
- Paradoxical Exudative Retinopathy and Macular Star Formation After Treatment Initiation in Coats Disease.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the first use the intravitreal anti-VEGF brolucizumab for the treatment of macular exudates and edema in a patient with Coats' disease. OBSERVATIONS: A 9-year-old boy was referred with a decrease in vision in the right eye. Visual acuity was 20/400 OD on presentation, and examination was remarkable for peripheral telangiectasias, exudates, microaneurysms, macular edema, and an inferior exudative retinal detachment. A diagnosis of Stage 3A2 Coats' disease was made, and the patient was treated with intravitreal bevacizumab as well as peripheral diode laser. However, on follow up, there was persistence of subretinal fluid accompanied by a decrease in visual acuity. The patient was then treated with intravitreal brolucizumab. Post injection visual and anatomical improvements were significant with complete resolution of macular edema within two weeks. Throughout the 5 months of follow up, there has been no re-accumulation of fluid and no further required therapy. CONCLUSIONS AND IMPORTANCE: Intravitreal brolucizumab was effective for the treatment of retinal edema and exudates in Coats' disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.